SCHEMBL4013417

SCHEMBL4013417

O=C(O)c1ccc(CNC(=O)c2cc(Cl)ccc2OCCc2ccc(F)cc2)cc1

nearest known ligand 0.76

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PTGER4 P35408 6/20 0.76
PTGER2 P43116 3/20 0.62
LMNA P02545 1/20 0.50
MAPT P10636 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
PYGL P06737 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.48
KMT2A Q03164 2/20 0.47
CYP1A2 P05177 1/20 0.47
CYP2C19 P33261 1/20 0.47
NR1H4 Q96RI1 1/20 0.46
EPHX2 P34913 1/20 0.46
AKR1C3 P42330 1/20 0.46
AKR1B1 P15121 1/20 0.46
MRGPRX4 Q96LA9 1/20 0.46
PPARG P37231 1/20 0.45
HTR2C P28335 1/20 0.45
SLC6A4 P31645 1/20 0.45
HTR2B P41595 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4014358 0.95 PTGER4 (0.67) PTGER4PTGER2LMNAL3MBTL1KMT2A
SCHEMBL4014415 0.93 PTGER4 (0.64) PTGER4PTGER2LMNAMAPTL3MBTL1
SCHEMBL27653404 0.88 PTGER4 (0.69) PTGER4PTGER2LMNAMAPTL3MBTL1
SCHEMBL10180681 0.88 PTGER4 (0.73) PTGER4PTGER2LMNAMAPTL3MBTL1
SCHEMBL4456806 0.86 PTGER4 (1.00) PTGER4PTGER2LMNAL3MBTL1PYGL
SCHEMBL4014975 0.85 PTGER4 (0.60) PTGER4PTGER2LMNAL3MBTL1SMN1; SMN2
SCHEMBL2242766 0.83 PTGER4 (0.66) PTGER4PTGER2LMNAMAPTL3MBTL1
SCHEMBL13770803 0.83 PTGER4 (0.66) PTGER4PTGER2LMNAMAPTL3MBTL1
SCHEMBL692054 0.83 PTGER4 (0.58) PTGER4PTGER2LMNAL3MBTL1KMT2A
SCHEMBL692571 0.83 PTGER4 (0.72) PTGER4PTGER2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1756043-B1 ORTHO SUBSTITUTED ARYL OR HETEROARYL AMIDE COMPOUNDS RAQUALIA PHARMA INC (JP) 2009-07-01 EP disclosed
EP-1756043-B1 ORTHO SUBSTITUTED ARYL OR HETEROARYL AMIDE COMPOUNDS RAQUALIA PHARMA INC (JP) 2009-07-01 EP disclosed
US-20090036495-A1 Combinations Comprising Alpha-2-Delta Ligands and Ep4 Receptor Antagonists PFIZER, INC. 2009-02-05 US disclosed
US-20050250818-A1 Ortho substituted aryl or heteroaryl amide compounds PFIZER INC 2005-11-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050250818-A1 Ortho substituted aryl or heteroaryl amide compounds OPRL1, PTGER1, OPRM1 PTGER4 19/4885PTGER2 6/4885LMNA 3070/4885
US-20090036495-A1 Combinations Comprising Alpha-2-Delta Ligands and Ep4 Receptor Antagonists PTGER4, PTGER2, OPRL1 PTGER4 1/4885PTGER2 2/4885LMNA 3019/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.